Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).
A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.
Predicting an individual's risk of ischemic stroke is difficult because thrombosis embolization-the process of a blood clot detaching from the area where it formed and traveling to and then sticking in another blood vessel-is based on factors that are unique to each person.
Women who experience pregnancy complications such as gestational diabetes, preeclampsia, or preterm delivery have a significantly increased long-term risk of developing peripheral artery disease (PAD) later in life, according to a new study published July 21st in the open access journal PLOS Medicine by Casey Crump of the University of Texas, US, and colleagues.
Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.
GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.
Is vaping bad for my health? As people who use e-cigarettes and their loved ones pose questions like this, growing scientific evidence shows that the answer is yes.
The American Heart Association and the American College of Cardiology, along with two other leading medical organizations have developed the first-ever guideline aimed at preventing and managing cardiovascular-kidney-metabolic (CKM) syndrome, an interconnected set of health conditions that significantly increase the risk of multiorgan complications and negative cardiovascular outcomes.
A study led by investigators from Johns Hopkins Medicine found that some patients with discoid lupus erythematosus - a form of skin lupus commonly diagnosed in young to middle-aged Black women that causes disc-shaped plaques to form on the body - were less likely to experience complications, such as diabetes, hypertension and coronary artery disease if they were prescribed hydroxychloroquine.
New data analyzing more than 20,000 patients from three major NIH studies show that elevated Lipoprotein(a) [Lp(a)] is associated with residual cardiovascular risk and warrants aggressive risk reduction.
Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment options experienced significant quality of life (QoL) improvements after undergoing transcatheter arterialization of the deep veins (TADV).
A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed that intensive LDL cholesterol lowering with evolocumab reduced cardiovascular events in high-risk patients without prior heart attack or stroke, with implications for future guideline updates.
Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.
A multi-institutional study led by the University of California, Davis, finds that living in urban areas with a higher percentage of visible trees is associated with a 4% decrease in cardiovascular disease.
Light intensity activities, like walking or household chores, were linked to a lower risk of death for people with cardiovascular-kidney-metabolic (CKM) syndrome, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are strongly associated with kidney, cardiovascular, and metabolic disease risk. It highlights suPAR as a stable biomarker of innate immune activation with potential pathogenic roles, while underscoring major gaps in assay standardization and therapeutic validation.
There is increasing evidence that gum disease is associated with increased risk of cardiovascular events, including heart attack, stroke, atrial fibrillation, heart failure and cardiometabolic health conditions. Effective prevention and treatment of gum disease, also called periodontal disease, could potentially decrease the burden of cardiovascular disease, according to a new scientific statement published today in the American Heart Association's flagship journal Circulation.
Long-term heart disease risk in women diagnosed with uterine fibroids was more than 80% higher than in women without fibroids, according to new independent research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses.
However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.